Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2019 Sep 23;191(38):E1049-E1056.
doi: 10.1503/cmaj.190344.

Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline

Nadia Fairbairn  1 , Josey Ross  2 , Michael Trew  2 , Karine Meador  2 , Jeff Turnbull  2 , Scott MacDonald  2 , Eugenia Oviedo-Joekes  2 , Bernard Le Foll  2 , Marie-Ève Goyer  2 , Michel Perreault  2 , Christy Sutherland  2
Affiliations
Practice Guideline

Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline

Nadia Fairbairn et al. CMAJ. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Marie-Ève Goyer reports receiving an honorarium and training from Gilead Sciences, outside of the submitted work. Bernard Le Foll reports receiving grants from Pfizer and Brainsway, Bioprojet, Alkermes, Canopy and the American Chemical Society, as well as nonfinancial support from Aurora, outside the submitted work. Josey Ross is employed by the BC Centre on Substance Use, the British Columbia node of the Canadian Research Initiative in Substance Misuse (CRISM). Christy Sutherland is employed by the BC Centre on Substance Use and is also the medical director of PHS Community Services Society, which provides injectable opioid agonist treatment. Michael Trew works for Alberta Health Services; the development of injectable opioid agonist treament clinics in Alberta have been partially funded through specific grants from the Alberta Ministry of Health for this work. Nadia Fairbairn reports receiving personal fees from British Columbia Centre on Substance Use, during the conduct of the study. No other competing interests were declared.

References

    1. Special Advisory Committee on the Epidemic of Opioid Overdoses. National report: apparent opioid-related deaths in Canada (June 2019). Ottawa: Public Health Agency of Canada; 2019.
    1. Woo A. In Vancouver, front-line workers are facing ‘a different kind of overdose’ in new synthetic drug. The Globe and Mail [Toronto] 2019. April 10.
    1. The Canadian Centre on Substance Abuse and Addiction and the Canadian Community Epidemiology Network on Drug Use. Deaths involving fentanyl in Canada, 2009–2014. Ottawa: The Canadian Centre on Substance Abuse and Addiction; 2015.
    1. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017;357:j1550. - PMC - PubMed
    1. Nosyk B, Marsh DC, Sun H, et al. Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996–2006. J Subst Abuse Treat 2010;39:22–31. - PubMed

Publication types

MeSH terms